Delcath establishes Queensbury facility

Delcath (New York), a company testing its treatment method for primary and metastatic cancers to the liver, said that it has signed a three-year lease with the option to buy on a 10,000 square foot facility in Queensbury, New York in which it plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP) System. The company anticipates hiring approximately 20 people at this facility by the end of 2009 to establish manufacturing, distribution, research and development capabilities.

The Delcath PHP System is being tested in a Phase III study for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The system is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments.

Clear Choice joins with TriZetto Group

Clear Choice Health Plans (Bend, Oregon) said that the company and Adaptis, its business process outsourcing (BPO) vendor, have mutually agreed to terminate their business relationship and that the company has entered into a five-year contract for BPO services with The TriZetto Group, an information technology and services company focused on the health care industry.

The agreement calls for TriZetto to provide claims administration, enrollment administration, billing, mailroom and business rules configuration services.

Xcorporeal now trading on pink sheets

Xcorporeal (Los Angeles) reported that, effective Sept. 4, the company's common stock commenced trading on the Pink Sheets Electronic OTC Market, an inter-dealer electronic quotation service for securities traded over-the-counter also known as the Pink Sheets, under the symbol "XCRP".

In addition, pursuant to the terms of the letter received from NYSE Amex LLC (formerly American Stock Exchange) on Aug. 20, 2009, the company's common stock has been suspended from trading on Amex. The company may seek in the future to have its common stock traded on the OTC Bulletin Board, but there can be no assurance that it will be successful in such efforts.

TDC expands facilities on both coasts

TDC Medical (Marlborough, Massachusetts) reported that they have grown into 15,000 square feet at 610 Palomar in Sunnyvale, California. Additionally, TDC Medical has increased its facilities in Marlborough from 13,000 square feet to 24,000 square feet, nearly doubling in size.

The new Marlborough facility consists of development labs, clean room and office space. The new Sunnyvale facility is a 15,000 square foot facility with a 3,200 square foot clean room, numerous engineering labs, and expanded office space. Both new facilities are within a few hundred feet of the former facilities.

TDC Medical services include concept brainstorming, design & engineering, prototyping and quality systems support, as well as turnkey manufacturing and production of finished sterile product.